Oxford Biotrans is a University of Oxford spin-out company supported by over 20 years of research by Dr Luet Lok Wong from the Department of Chemistry. The company will develop and commercialise enzymatic process technologies that yield high-value chemical compounds.
Our processes bring the following benefits:
- Yield natural-grade products from natural feedstocks.
- Offer security of supply by using readily-available feedstocks.
- Realise production cost advantages, deriving from:
- Selectivity and activity of our proprietary, bespoke biocatalysts.
- Ability to use low-cost feedstocks.
They are environmentally friendly process that avoid the harsh reagents and conditions of many synthetic processes, thus producing less chemical waste and using less energy.
Moreover, we can provide routes to molecules not easily accessed by any other means due to the pronounced ability of our catalysts to functionalise positions of a molecular framework that would ordinarily be considered inactive.
Jason has over fifteen years’ technology-SME experience with a focus on industrial catalysis and catalyst discovery as a director/VP of Avantium Technologies B.V. and hte AG.
Will has worked internationally up to Vice President level in the chemicals sector and most recently as COO for Oxford Catalysts, and at the Technology Strategy Board.
George RobinsonNon-Executive Director
George is a Partner and co-Founder of Sloane Robinson LLP, an investment management business which invests in listed equities globally with a particular focus on Asian and Emerging Markets. Prior to that he worked for 15 years in Asia, initially for John Swire and Sons in Hong Kong, Korea and the Philippines, and then for Asian based stockbroker WI Carr in Korea, Thailand and Hong Kong where he was Director of Regional Research. George is an active investor in early stage technology and biotech companies with a particular focus on Oxford spin- outs, and is a founding Partner of Technikos, a private equity partnership which invests in spin-out companies from the Oxford Institute of Biomedical Engineering. He is an investor in a number of Oxford based companies and a partner of Oxford Investments Consultants LLP which advises the Oxford Technology and Innovations EIS Fund. He is an honorary fellow of Keble College, Oxford from where he graduated with an MA in Engineering Science, and is a member of Oxford University Endowment Investment Committee.
Robert BahnsNon-Executive Director
Robert is Director of Technology Ventures at Touchstone Innovations where he focusses on investments in the hardware and materials sectors. He has over fifteen years’ experience in venture capital and prior to joining Innovations was a Director in the technology investment team at Nomura International plc, where he led investments in the communications and electronics sectors. He trained as an electronics engineer and worked in Japan for Pioneer Electronics Corporation, both in R&D and in establishing the company’s first UK manufacturing facility. He has an MBA from Insead and an Electrical Sciences degree from the University of Cambridge. Robert is on the board of CCS, GKN-Evo eDrive Systems, Impression Technologies, Plaxica, Drayson Wireless, Sub Salt Solutions and Oxford Biotrans.
James is Director at Oxford Spin-Out Equity Management (OSEM). James joined Isis Innovation Ltd in April 2003 to manage the University’s equity stakes in spin-out companies and joined Oxford Spin-out Equity Management (OSEM) on its formation in August 2008. Prior to Isis, James worked in the private equity group at Abbey National Treasury Services as a member of a team responsible for commitments of £1.9bn. He has also been a member of the Strategic Advisory Board of funds managed by Advent Venture Partners and Avlar BioVentures. James gained his first degree in Engineering Science at the University of Oxford, following which he trained and worked as a software engineer, initially with Marconi Underwater Systems. He gained an MBA from Cranfield in 1990 and has over 17 years of experience in venture capital as both investor and adviser.
Luet WongScientific Advisor
Luet is a University Lecturer in Chemistry and the EP Abraham Cephalosporin Trust Fellow and Tutor in Inorganic Chemistry at St Hugh’s College, University of Oxford. He provides Oxford Biotrans with scientific and technical leadership.
Vicki HarperOffice Manager
Vicki has over 25 years’ experience in office administration. Previous roles include Office Manager for Velocys plc (formerly Oxford Catalysts) and PA to the Managing Director (UK & Ireland) of The Nielsen Group in Oxford.
Matthew HodgesDirector of Commercial Operations
Matthew has a background in molecular biology, having first received a BA in Biological Sciences, followed by a D.Phil from the University of Oxford. He subsequently spent 3 years at Mars & Co. Consulting where he worked across the FMCG, Life Sciences, Agrochemical, Auto and Aerospace industries in a broad range of commercial engagements, including corporate strategy, product strategy, commercial due diligence and valuation.
Mohamed IssoufFermentation Development & Scale-up Manager
Mohamed has over 11 years’ experience working for start-ups/SMEs, leading scientific projects for the biotechnology industry. Previously Mohamed worked as senior scientist/ team leader at Aquapharm Biodiscovery Ltd in Scotland which was focused on the discovery and development of new natural products from marine micro-organisms. Mohamed holds an MSc in microbiology and biochemistry from the University of Luminy (Marseille).
Kouider GuerinikSenior Scientist
Kouider has over 24 years experience in Biotechnology spanning diverse sectors: food, chemicals, environment and oil industries. Previously Kouider worked at Saudi Aramco’s R&D centre on the application of Biotech to the oil industry, and at Unilever Research, where he worked on a number of bioconversion/biocatalytic processes.
Toni FlemingSenior Scientist
Toni has over 20 years’ experience in molecular biology and protein biochemistry gained in academic and pharmaceutical organisations. She has worked in the biocatalysis teams of Piramal Healthcare and Dr Reddy’s Laboratories. Toni has a degree from Exeter University and a PhD from Queen Mary, University of London.
Rik HallewellPRD Manager
Rik has 16 years industrial experience and has previously worked for Oxford Asymmetry International, Evotec and Aptuit in the development and scale-up of API processes to cGMP. Rik has a degree and PhD in chemistry from the University of Salford, UK.
Donna graduated from the University of Bath in 2004, achieving an undergraduate Masters degree in Biochemistry. She has since worked in a number of roles in both academic and commercial settings, focusing largely on the overexpression and purification of recombinant proteins.
Jay has over 8 years of biotech industry experience covering screening, upstream and downstream process development with process transfer from lab scale to large manufacturing scale fermentations. Jay has previously worked at Lallemand group, Aquapharm Biodiscovery Ltd, IFFCO and National Science Laboratory (Edinburgh) on varied roles. Jay is responsible for the scale up of P450 enzyme production process at Oxford Biotrans. Jay holds an MSc in Biomedical Sciences & Microbiology from the Edinburgh Napier University.
Scott is a recent graduate from Scotland with a keen interest in cellular biology and biotechnology. Previous work at Croda, Liverpool and NHS Scotland has led him to apply himself to current industrial practices. As one of Oxford Biotrans’ youngest members, Scott is ready to break into the industry. Scott holds a BSc from the University of Glasgow and a MSc in industrial biotechnology from the University of Strathclyde in collaboration with the IBioIC.
Matthew is responsible for ensuring the scalability of processes, and bridging the gap between laboratory and plant scale work. Previously, Matthew was a process chemist at Robinson Brothers Ltd., where he led projects from concept through to plant synthesis, and was part of the group which received the GSK Innovation Award at the 2014 Chemical Industry Awards. Matthew holds an MSci in chemistry from the University of Birmingham, UK.
Sam is involved in the development of P450’s biocatalytic properties and has 2 years previous experience at the Universities of Oxford and Hull, in fields of biotech research ranging from epigenetics to electrochemistry. He holds an MBiochem from the University of Oxford, UK.
Caitlin joined the team in July 2016 after spending her Masters year working in the Wong group on P450 biotransformations with sesquiterpene compounds. She has recently graduated with an MChem from the University of Oxford.